Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2005-2010

ABSTRACT

The National Health Plan 2001-2010 calls for investigation of the feasibility of pneumococcal vaccines for Papau New Guinea. The Papua New Guinea (PNG) Institute of Medical Research, the Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia will collaborate to examine very closely the safety of neonatal vaccination, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries. Detailed Description In order to obtain the earliest possible protection against invasive pneumococcal disease, achieve optimal coverage and reduce burden of early carriage, neonatal pneumococcal conjugate vaccine (PCV) immunization needs to be considered. This study in the PNG highlands will enrol 312 infants at birth, who will be randomised to receive PCV either at 1-2-3 months (infant schedule according to PNG national EPI schedule) or 0-1-2 months of age (neonatal schedule) or receive only routine immunizations (controls). Blood samples will be taken at birth-2-3-4 months of age, pre- and post-pneumococcal polysaccharide booster (23vPPV) at 9-10 months of age (to assess immune memory) and at 18 months at study completion. Carriage will be assessed weekly for the first month of life and at regular intervals thereafter. There will be ongoing surveillance for respiratory and other diseases throughout the study. In addition to serotype-specific IgG, we will examine IgG avidity, IgG subclasses, mucosal IgA and T-cell cytokine responses to PCV and pneumococcal protein antigens. To ensure immunological safety, particularly for neonatal PCV, immune responses to concomitant vaccines and viral and environmental antigens will also be examined as well as overall T-cell maturation. More... »

URL

https://clinicaltrials.gov/show/NCT00219401

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The National Health Plan 2001-2010 calls for investigation of the feasibility of pneumococcal vaccines for Papau New Guinea. The Papua New Guinea (PNG) Institute of Medical Research, the Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia will collaborate to examine very closely the safety of neonatal vaccination, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries.\n\nDetailed Description\nIn order to obtain the earliest possible protection against invasive pneumococcal disease, achieve optimal coverage and reduce burden of early carriage, neonatal pneumococcal conjugate vaccine (PCV) immunization needs to be considered. This study in the PNG highlands will enrol 312 infants at birth, who will be randomised to receive PCV either at 1-2-3 months (infant schedule according to PNG national EPI schedule) or 0-1-2 months of age (neonatal schedule) or receive only routine immunizations (controls). Blood samples will be taken at birth-2-3-4 months of age, pre- and post-pneumococcal polysaccharide booster (23vPPV) at 9-10 months of age (to assess immune memory) and at 18 months at study completion. Carriage will be assessed weekly for the first month of life and at regular intervals thereafter. There will be ongoing surveillance for respiratory and other diseases throughout the study. In addition to serotype-specific IgG, we will examine IgG avidity, IgG subclasses, mucosal IgA and T-cell cytokine responses to PCV and pneumococcal protein antigens. To ensure immunological safety, particularly for neonatal PCV, immune responses to concomitant vaccines and viral and environmental antigens will also be examined as well as overall T-cell maturation.", 
    "endDate": "2010-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00219401", 
    "keywords": [
      "blood sample", 
      "safety", 
      "immunization", 
      "IgG subclass", 
      "pneumococcal conjugate vaccine", 
      "burden", 
      "pneumococcal polysaccharide", 
      "protection", 
      "University of Western Australia", 
      "life", 
      "cytokine response", 
      "study completion", 
      "immune response", 
      "immune memory", 
      "national health", 
      "development", 
      "carriage", 
      "Papua New Guinea", 
      "surveillance", 
      "avidity", 
      "infant", 
      "enroll", 
      "serotypes", 
      "Guinea", 
      "vaccination", 
      "feasibility", 
      "T cell maturation", 
      "control", 
      "age", 
      "protein antigen", 
      "vaccine", 
      "mucosal IgA", 
      "child health research", 
      "Parturition", 
      "unique opportunity", 
      "environmental antigen", 
      "invasive pneumococcal disease", 
      "Institute", 
      "regular interval", 
      "pneumococcal vaccine", 
      "Australian scientist", 
      "Papua Guinea", 
      "coverage", 
      "disease", 
      "immunity", 
      "country"
    ], 
    "name": "Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00219401"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00002.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.417153.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.465226.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.1012.2", 
        "type": "Organization"
      }
    ], 
    "startDate": "2005-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.vaccine.2011.05.065", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010470009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s41479-016-0014-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016313248", 
          "https://doi.org/10.1186/s41479-016-0014-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s41479-016-0014-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016313248", 
          "https://doi.org/10.1186/s41479-016-0014-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/cvi.00247-09", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027225226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vaccine.2008.12.046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034174828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0056698", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039460277"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.vacrep.2016.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046276715"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0185877", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092196583"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00219401"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00219401'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00219401'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00219401'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00219401'


 

This table displays all metadata directly associated to this object as RDF triples.

94 TRIPLES      16 PREDICATES      71 URIs      55 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00219401 schema:about anzsrc-for:3103
2 anzsrc-for:3177
3 schema:description The National Health Plan 2001-2010 calls for investigation of the feasibility of pneumococcal vaccines for Papau New Guinea. The Papua New Guinea (PNG) Institute of Medical Research, the Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia will collaborate to examine very closely the safety of neonatal vaccination, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries. Detailed Description In order to obtain the earliest possible protection against invasive pneumococcal disease, achieve optimal coverage and reduce burden of early carriage, neonatal pneumococcal conjugate vaccine (PCV) immunization needs to be considered. This study in the PNG highlands will enrol 312 infants at birth, who will be randomised to receive PCV either at 1-2-3 months (infant schedule according to PNG national EPI schedule) or 0-1-2 months of age (neonatal schedule) or receive only routine immunizations (controls). Blood samples will be taken at birth-2-3-4 months of age, pre- and post-pneumococcal polysaccharide booster (23vPPV) at 9-10 months of age (to assess immune memory) and at 18 months at study completion. Carriage will be assessed weekly for the first month of life and at regular intervals thereafter. There will be ongoing surveillance for respiratory and other diseases throughout the study. In addition to serotype-specific IgG, we will examine IgG avidity, IgG subclasses, mucosal IgA and T-cell cytokine responses to PCV and pneumococcal protein antigens. To ensure immunological safety, particularly for neonatal PCV, immune responses to concomitant vaccines and viral and environmental antigens will also be examined as well as overall T-cell maturation.
4 schema:endDate 2010-05-01T00:00:00Z
5 schema:keywords Australian scientist
6 Guinea
7 IgG subclass
8 Institute
9 Papua Guinea
10 Papua New Guinea
11 Parturition
12 T cell maturation
13 University of Western Australia
14 age
15 avidity
16 blood sample
17 burden
18 carriage
19 child health research
20 control
21 country
22 coverage
23 cytokine response
24 development
25 disease
26 enroll
27 environmental antigen
28 feasibility
29 immune memory
30 immune response
31 immunity
32 immunization
33 infant
34 invasive pneumococcal disease
35 life
36 mucosal IgA
37 national health
38 pneumococcal conjugate vaccine
39 pneumococcal polysaccharide
40 pneumococcal vaccine
41 protection
42 protein antigen
43 regular interval
44 safety
45 serotypes
46 study completion
47 surveillance
48 unique opportunity
49 vaccination
50 vaccine
51 schema:name Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea
52 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00219401
53 schema:sdDatePublished 2019-03-07T15:21
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher N2c36cbcf562344f586eb112668af77d8
56 schema:sponsor https://www.grid.ac/institutes/grid.1012.2
57 https://www.grid.ac/institutes/grid.417153.5
58 https://www.grid.ac/institutes/grid.465226.1
59 schema:startDate 2005-05-01T00:00:00Z
60 schema:subjectOf sg:pub.10.1186/s41479-016-0014-x
61 https://doi.org/10.1016/j.vaccine.2008.12.046
62 https://doi.org/10.1016/j.vaccine.2011.05.065
63 https://doi.org/10.1016/j.vacrep.2016.08.002
64 https://doi.org/10.1128/cvi.00247-09
65 https://doi.org/10.1371/journal.pone.0056698
66 https://doi.org/10.1371/journal.pone.0185877
67 schema:url https://clinicaltrials.gov/show/NCT00219401
68 sgo:license sg:explorer/license/
69 sgo:sdDataset clinical_trials
70 rdf:type schema:MedicalStudy
71 N2c36cbcf562344f586eb112668af77d8 schema:name Springer Nature - SN SciGraph project
72 rdf:type schema:Organization
73 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
74 rdf:type schema:DefinedTerm
75 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
76 rdf:type schema:DefinedTerm
77 sg:pub.10.1186/s41479-016-0014-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016313248
78 https://doi.org/10.1186/s41479-016-0014-x
79 rdf:type schema:CreativeWork
80 https://doi.org/10.1016/j.vaccine.2008.12.046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034174828
81 rdf:type schema:CreativeWork
82 https://doi.org/10.1016/j.vaccine.2011.05.065 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010470009
83 rdf:type schema:CreativeWork
84 https://doi.org/10.1016/j.vacrep.2016.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046276715
85 rdf:type schema:CreativeWork
86 https://doi.org/10.1128/cvi.00247-09 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027225226
87 rdf:type schema:CreativeWork
88 https://doi.org/10.1371/journal.pone.0056698 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039460277
89 rdf:type schema:CreativeWork
90 https://doi.org/10.1371/journal.pone.0185877 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092196583
91 rdf:type schema:CreativeWork
92 https://www.grid.ac/institutes/grid.1012.2 schema:Organization
93 https://www.grid.ac/institutes/grid.417153.5 schema:Organization
94 https://www.grid.ac/institutes/grid.465226.1 schema:Organization
 




Preview window. Press ESC to close (or click here)


...